The 23rd European Congress of Pathology of the European Society of Pathology (ECP 2011) was held in Helsinki, Finland on 27 August – 1 September.
At ECP 2011, an AstraZeneca sponsored satellite symposium entitled ‘EGFR mutation testing in advanced NSCLC: best practice and future perspectives’ was held. The symposium was presented by an international panel of leading pathology and oncology experts:
- Dr Nicola Normanno (Italy; Chairman)
- Professor Keith Kerr (UK)
- Professor Marc Denis (France)
The symposium highlighted best practice for EGFR mutation testing in patients with advanced non-small-cell lung cancer (NSCLC) and focused specifically on currently available testing methodologies, techniques and sample considerations. The faculty also examined the role of the pathologist as part of a multidisciplinary team involved in the diagnosis and management of EGFR mutation-positive NSCLC. The future outlook for EGFR mutation testing was also considered, including discussion regarding newer testing methodologies and the incorporation of EGFR mutation testing into a broader testing strategy for a range of NSCLC predictive markers.
Click on the image below to view the full video and slides of the symposium
Please note that this symposium contains information about the first-line use of gefitinib in EGFR mutation-positive advanced NSCLC. Gefitinib product licences vary from country to country and not all licences include first-line use in EGFR mutation-positive advanced NSCLC. Please consult your local prescribing information.
Professor Keith Kerr: Clinical implications of symposium topics
Dr Nicola Normanno and Professor Marc Denis: Presentation highlights